Ann: Preliminary Final Report, page-9

The underlying point, and one that is all too often not grasped by blow-ins who joined the stock on a whim surrounding the MM hype, is that ESE isn't like your 'traditional' mc companies - like BDA, which by the way is tracking along somewhat nicely with revenue. In fact, the view that ESE is like these other companies is in itself, an ill considered view.

In relative terms, ESE has had a 'ready-made' product for an extensive period, combined with far fewer regulatory challenges by way of the fact the terpenes it develops ommit cannabinoid properties.

This was one of the major elements the company promoted at the time of its IPO, and if anything, the distraction around licensing and local/international changes in drug regulations - which is what other MC companies are dealing with and thus preventing them from making revenue - has taken away from the fact that there is/was a distinct competitive advantage for ESE that seemingly isn't being capitalised upon. Also, since when did it become the norm to accept mediocrity because others aren't fulfilling their own potential?

It's evident we both want the best for the company but with different views on how (or who) to get us there. So we'll leave it at that and you too have a nice day